The impact of prolonged antifungal therapy on the development of resistance was examined in 61 patients with oropharyngeal thrush. Fifty-nine patients had symptomatic human immunodeficiency virus infection, one had lung cancer, and one had metastatic prostate cancer. Cultures of pharyngeal samples from all patients were positive for yeasts and included 57 (93.4%) Candida albicans, 3 (4.9%) Candida glabrata, and 1 (1.6%) Candida krusii. Of 61 patients, 32 (52.5%) were receiving or had recently received antifungal therapy. Clotrimazole was the most commonly prescribed azole, followed by ketoconazole and fluconazole. Two patients had received amphotericin B therapy and one had received flucytosine. The duration of therapy with clotrimazole, ketoconazole, and fluconazole ranged from 3 to 240, 14 to 44, and 7 to 138 days, respectively. There was no overall difference in the susceptibilities of the clinical isolates from treated and untreated patients to amphotericin B, nystatin, flucytosine, clotrimazole, ketoconazole, and fluconazole. A C. albicans isolate from one patient who had clinically failed on ketoconazole, fluconazole, and amphotericin B was resistant to these drugs. The lack of difference in the susceptibility pattern indicates that clinically significant emergence of resistance does not occur in those patients who receive prolonged antifungal therapy.
Oral lesions caused by Candida species are frequently seen in patients with human immunodeficiency virus (HIV) infection and patients receiving immunosuppressive therapy. In fact, the presence of oral candidiasis has been shown to be the earliest opportunistic infection in patients infected with HIV (12) . Although candidal stomatitis, oropharyngitis, or esophagitis rarely progresses to become a life-threatening disease, patients with AIDS need long-term antifungal treatment so that they can eat without pain and clinical nutritional deficiency can be delayed (5, 15, 18) .
In the past, prolonged antibacterial therapy has predictably produced resistant bacterial isolates (14, 19) . Although HIV-infected patients on antifungal therapy have complained of persistent symptoms, rarely has the possibility of infection with a resistant yeast isolate been entertained or investigated. The more common scenario is to suspect cytomegalovirus or other herpesvirus involvement (1, 8, 10) . In our population, we examined whether prolonged antifungal therapy could lead to a significant development of resistance to antifungal agents in yeasts. and was used in a microdilution procedure (20) . Several colonies of each yeast isolate were inoculated into 3 ml of the liquid test medium without DMSO and were incubated for 3 h. After incubation, the density was adjusted to 0.5 MacFarland standard in the medium without DMSO and further diluted 100-fold prior to inoculation of an equal volume of medium containing an antifungal agent. The final inoculum size was confirmed by quantitative culture to be 5 x 104 CFU/ml. The microtiter wells were examined after incubation for 24 and 48 h at 35°C. The MIC was interpreted to be the lowest concentration at which a clear reduction in growth or no growth was attained.
MATERIALS AND METHODS

RESULTS
Patient profile and yeasts isolated. A total of 61 patients were evaluated for the presence of oral mucocutaneous lesions. The demographic and medical characteristics of the patients are given in Table 1 . Fifty-nine patients had symptomatic HIV infections, while two patients had hematologic or oncologic malignancies. One yeast strain was isolated from all patients. C. albicans was the most frequently recovered species (57 of 61 patients [93.4%]), followed by C. glabrata and C. krusii. A total of 32 patients were either receiving or had recently been treated with antifungal agents. Clotrimazole was the most frequently prescribed antifungal agent, followed by ketoconazole, fluconazole, and amphotericin B. Amphotericin B was used in the treatment of Cryptococcus neoformans meningitis in one patient. The median number of days of therapy was 42 (range, 3 to 240 days) for clotrimazole, 21 (range, 14 to 44 days) for ketoconazole, and 48 (range, 7 to 158 days) for fluconazole ( Table 2) .
Comparative susceptibilities of yeasts. The respective MICs of amphotericin B were 0.5 ,ug/ml for the control strains C.
albicans ATCC 64546 and ATCC 64552, the respective MICs of ketoconazole were 8.0 and 1.0 pLg/ml for C. albicans ATCC 64546 and ATCC 64550, and the respective MICs of 5-flucytosine were 8 and >64.0 p.g/ml for C. albicans ATCC Table 3 ). For control strains of C. albicans ATCC 64544, ATCC 64546, and ATCC 64550, the MICs were 8 ,ug/ml. The antifungal susceptibilities of the 61 clinical isolates were compared between isolates from those patients who were currently receiving or who had previously been treated with antifungal therapy and isolates from those patients who had never received antifungal therapy. No significant differences were observed in the MICs of amphotericin B, nystatin, ketoconazole, or fluconazole, flucytosine, and clotrimazole between the two groups ( Fig. 1 through 6, respectively) . The distributions of resistant isolates from the treated and untreated groups were identical.
One patient who had esophagitis and oropharyngeal thrush was treated with ketoconazole and amphotericin B. After several weeks of therapy, oropharyngeal pain recurred. Oral flucytosine was administered, and the patient reported dramatic relief. For the C. albicans strain that was isolated during the relapse, the MICs of amphotericin B, ketoconazole, and fluconazole were much higher (4, >64, and >64 ,ug/ml, respectively) and the MIC of 5-flucytosine was low (<2 ,ug/ml).
DISCUSSION
The emergence of bacterial resistance in patients after prolonged use of antibiotic therapy is well known and may be inevitable (14) . The use of broad-spectrum antibiotics alters the normal bacterial flora and allows the more resistant bacteria to colonize. A scenario of population selection in yeasts similar to that observed in bacteria is the emergence of C. glabrata into the clinical arena because of its inherently greater resistance to azole compounds (11) . With antibacterial therapy there is a separate mechanism of resistance, that of de novo mutational resistance, that is seen with Staphylococcus aureus and ciprofloxacin (17) . A counterpart of that type of resistance in yeasts is the flucytosine resistance seen during therapy (3). De novo resistance to polyenes is very rare in fungi (4), partly because of their irreversible fungicidal action once they are bound to the yeast cells (7) . (Fig. 1), nystatin (Fig. 2) , ketoconazole (Fig. 3) , fluconazole (Fig. 4) , flucytosine (Fig. 5) , and clotrimazole (Fig. 6 ). The number of dilutions which still inhibited growth is shown on the abscissa. The more resistant organisms are on the left. Rx +, treated patients; Rx -, untreated patients.
With the advent of AIDS, the use of antifungal agents has increased. Some HIV-infected patients with cryptococcal infections may require antifungal therapy for life (6) . Most patients with symptomatic HIV infections or AIDS require long-term antifungal therapy either as treatment or as prophylaxis of oral and esophageal thrush (5) . Resistance to antifungal agents in yeast isolates from patients with AIDS has been reported (13) , but a correlation between antifungal therapy and resistance has not been adequately addressed previously.
In our study, we evaluated only those immunocompromised patients with symptomatic oral thrush that necessitated a fungal culture. The selection of media for fungal susceptibility testing has always been a point of contention (9) . The 
